AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25875387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23837673 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training
Number of subjects: 60
Study 23837673 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 60
Study 23837673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 60
Study 23837673 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status, post test verbal memory performance, executive functioning measures
Number of subjects: 60
Study 23837673 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation to treatment group
Number of subjects: 60
Study 21034687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy + risperidone
Number of subjects: 115
Study 21034687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy + placebo
Number of subjects: 115
Study 21034687 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy + placebo
Number of subjects: 115
Study 21034687 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (cognitive therapy + risperidone, cognitive therapy + placebo, supportive therapy + placebo)
Number of subjects: 115
Study 19125906 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR (12.5-50 mg/day)
Number of subjects: 72
Study 19125906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19125906 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 72
Study 17300798 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of goal neglect in preschool children
Number of subjects: 0
Study 17300798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional Change Card Sort (DCCS)
Number of subjects: 0
Study 17300798 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposite color response inhibition task
Number of subjects: 0
Study 14517708 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg daily for 6 days)
Number of subjects: 8
Study 14517708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11063909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocotrienyl acetate (250 mg/d)
Number of subjects: 51
Study 11063909 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-tocotrienyl acetate (250 mg/d)
Number of subjects: 51
Study 11063909 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-tocotrienyl acetate (250 mg/d)
Number of subjects: 51
Study 11063909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8817801 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment A
Number of subjects: 0
Study 8817801 — intervention group
Group type: COMPARATOR
Intervention: treatment B
Number of subjects: 0
Study 1433686 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE, 15 mg)
Number of subjects: 816
Study 1433686 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE, 1 mg)
Number of subjects: 816
Study 1433686 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose norepinephrine (NE, 11 mg)
Number of subjects: 816
Study 1433686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category score for HDE
Number of subjects: 816
Study 1433686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category score for NE
Number of subjects: 816
Study 1433686 — intervention group
Group type: COMPARATOR
Intervention: Cerebral Performance Category score for SDE
Number of subjects: 816
Study 3001605 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20
Study 3001605 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20
Study 3001605 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide
Number of subjects: 20
Study 31698361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin plus aspirin
Number of subjects: 187
Study 31698361 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 187
Study 31698361 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary PlGF concentrations at mid-pregnancy
Number of subjects: 187
Study 28832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5ug twice daily (group II)
Number of subjects: 324
Study 28832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9ug twice daily (group III)
Number of subjects: 324
Study 28832630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5ug twice daily with tiotropium 18ug once daily (group IV)
Number of subjects: 324
Study 28832630 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18ug once daily (group I)
Number of subjects: 324
Study 25879343 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,000 mg/m² daily) and oxaliplatin (85 mg/m² IV)
Number of subjects: 42
Study 25879343 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (350 mg/m²) and leucovorin (20 mg/m²)
Number of subjects: 42
Study 23290547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 μg)
Number of subjects: 40
Study 23290547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21088675 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-heparin infusion
Number of subjects: 9
Study 21088675 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 19720764 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring device
Number of subjects: 591
Study 19720764 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 591
Study 17868864 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment modalities for myeloproliferative HES
Number of subjects: 0
Study 17868864 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment modalities for idiopathic HES
Number of subjects: 0
Study 17868864 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment modalities for lymphocytic‐variant HES
Number of subjects: 0
Study 15521004 — intervention group
Group type: EXPERIMENTAL
Intervention: BILN 2061 500 mg twice daily for 2 days
Number of subjects: 51
Study 15521004 — intervention group
Group type: EXPERIMENTAL
Intervention: BILN 2061 200 mg twice daily for 2 days
Number of subjects: 51
Study 15521004 — intervention group
Group type: EXPERIMENTAL
Intervention: BILN 2061 25 mg twice daily for 2 days
Number of subjects: 51
Study 15521004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11161394 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m² at day 1-3)
Number of subjects: 40
Study 11161394 — intervention group
Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 40
Study 11161394 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study 9788689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9788689 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (topical steroid treatment)
Number of subjects: 29
Study 9788689 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (topical antihistamine)
Number of subjects: 29
Study 9788689 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF (Stem Cell Factor) presence in nasal lavage fluids
Number of subjects: 29
Study 9788689 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal antibody against SCF
Number of subjects: 29
Study 7633557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide (250 micrograms)
Number of subjects: 66
Study 7633557 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline (placebo)
Number of subjects: 66
Study 2791180 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IV prochlorperazine
Number of subjects: 100
Study 2791180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 321183 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac 200 mg twice daily
Number of subjects: 31
Study 321183 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin 3.6 g daily
Number of subjects: 31
Study 321183 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 321183 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin
Number of subjects: 31
Study 31900997 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled verapamil (10 mg)
Number of subjects: 20
Study 31900997 — intervention group
Group type: COMPARATOR
Intervention: Control (4 cc nebulized distilled water)
Number of subjects: 20
Study 31117986 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0
Study 31117986 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 29057836 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CM) 6 g
Number of subjects: 9
Study 29057836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 26150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training in 38°C (T38)
Number of subjects: 7
Study 26150574 — intervention group
Group type: COMPARATOR
Intervention: Heat training in 18°C (T18)
Number of subjects: 7
Study 26150574 — intervention group
Group type: COMPARATOR
Intervention: Blood volume expansion with albumin solution in 38°C (T38A)
Number of subjects: 7
Study 26150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training effects on plasma volume
Number of subjects: 7
Study 26150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training effects on mean sweat output
Number of subjects: 7
Study 26150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training effects on sweat [Na(+)]
Number of subjects: 7
Study 26150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training effects on MCAvmean
Number of subjects: 7
Study 26150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Q̇max before and after training in 38°C
Number of subjects: 7
Study 23782502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 211
Study 23782502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 211
Study 23782502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Pioglitazone
Number of subjects: 211
Study 23782502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 21726984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 1g every 8 h (q8h) for 24 h
Number of subjects: 8
Study 21726984 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h infusion of 1 g q8h for 24 h
Number of subjects: 8
Study 21726984 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h infusion of 2 g q8h for 24 h
Number of subjects: 8
Study 21726984 — intervention group
Group type: EXPERIMENTAL
Intervention: All three regimens of meropenem
Number of subjects: 8
Study 19292653 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure by seed-pressure method
Number of subjects: 71
Study 19292653 — intervention group
Group type: COMPARATOR
Intervention: Control group (plain adhesive patch)
Number of subjects: 71
Study 17006839 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mCi of (131)I
Number of subjects: 224
Study 17006839 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mCi of (131)I
Number of subjects: 224
Study 12680181 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 500 mg/m2 on days 1 and 2 plus epidoxorubicin 90 mg/m2 on day 1 every 3 weeks (group A)
Number of subjects: 58
Study 12680181 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2/cycle plus doxorubicin 50 mg/m2/cycle every 3 weeks (group B)
Number of subjects: 58
Study 12680181 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2/cycle plus epidoxorubicin 90 mg/m2/cycle every 21 days (group C)
Number of subjects: 58
Study 10587129 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal venous-dominant phase CT
Number of subjects: 300
Study 10587129 — intervention group
Group type: COMPARATOR
Intervention: Hepatic arterial-dominant phase CT
Number of subjects: 300
Study 10587129 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced images
Number of subjects: 300
Study 10587129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall lesion detection
Number of subjects: 300
Study 9085509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound-induced autonomic arousals
Number of subjects: 63
Study 9085509 — intervention group
Group type: COMPARATOR
Intervention: Current definitions of arousals
Number of subjects: 63
Study 1676891 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mEq/day NaCl diet
Number of subjects: 27
Study 1676891 — intervention group
Group type: COMPARATOR
Intervention: 200 mEq/day NaCl diet
Number of subjects: 27
Study 6756530 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 6756530 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 4054064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical application of 0.1 mg Sulprostone‐Tylose gel
Number of subjects: 10
Study 4054064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with local prostaglandin)
Number of subjects: 10
Study 31765659 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μm of androstadienone (AND)
Number of subjects: 52
Study 31765659 — intervention group
Group type: COMPARATOR
Intervention: Placebo odor
Number of subjects: 52
Study 30076108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy boost with 23 fractions of IMRT and 2 fractions of brachytherapy
Number of subjects: 0
Study 30076108 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT) alone with 44 fractions
Number of subjects: 0
Study 25845835 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially reduced exposure tobacco products
Number of subjects: 136
Study 24999282 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom
Number of subjects: 224
Study 24999282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 22552183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813
Study 22552183 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological therapy)
Number of subjects: 813
Study 20167900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored materials including personalized risk feedback
Number of subjects: 596
Study 20167900 — intervention group
Group type: COMPARATOR
Intervention: General educational materials
Number of subjects: 596
Study 18541356 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-night sleep (rich in REM sleep)
Number of subjects: 0
Study 18541356 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-night sleep (rich in SWS)
Number of subjects: 0
Study 15793381 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 57
Study 15793381 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 57
Study 12641687 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% 1 ml.kg(‐1) (group B, n = 15)
Number of subjects: 30
Study 12641687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% 1 ml.kg(‐1) and preservative‐free s‐ketamine 0.5 mg.kg(‐1) (group K, n = 15)
Number of subjects: 30
Study 10682152 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (200 mg three times daily) plus Lamivudine (300 mg twice daily)
Number of subjects: 106
Study 10682152 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg three times daily) plus Lamivudine (300 mg twice daily) plus Loviride (100 mg three times daily)
Number of subjects: 106
Study 8917255 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin (7,000 U bolus before PTCA, followed by 10,500 U infusion over 24 h, then 3,500 U subcutaneous application twice daily for 28 days)
Number of subjects: 625
Study 8917255 — intervention group
Group type: COMPARATOR
Intervention: Control (10,000 U unfractionated heparin bolus followed by 24,000 U infusion over 24 h, then subcutaneous placebo injections for 28 days)
Number of subjects: 625
Study 8917255 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 625
Study 8917255 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 625
Study 1888046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) 15 micrograms.kg‐1
Number of subjects: 22
Study 1888046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1888046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS)
Number of subjects: 22
Study 6802018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous administration of 18 mg/h dihydralazine and 0.6 mg/h nitroglycerin
Number of subjects: 0
Study 6802018 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin only
Number of subjects: 0
Study 6802018 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 30476315 — intervention group
Group type: EXPERIMENTAL
Intervention: brief cognitive behavioral therapy (bCBT)
Number of subjects: 0
Study 30476315 — intervention group
Group type: COMPARATOR
Intervention: enhanced usual care
Number of subjects: 0
Study 30476315 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 0
Study 30236042 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sinecatechins (TS) 10% applied twice daily after CO2 laser treatment; 60 subjects in this group.
Number of subjects: 87
Study 30236042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment); 27 subjects in this group.
Number of subjects: 87
Study 30236042 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sinecatechins (TS) 10% applied twice daily; 60 subjects in this group.
Number of subjects: 87
Study 28863316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal Contraceptives (HC)
Number of subjects: 130
Study 28863316 — intervention group
Group type: COMPARATOR
Intervention: No-Hormonal Contraceptives (no-HC)
Number of subjects: 130
Study 28863316 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 130
Study 26888572 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation with aortic stenosis (AS)
Number of subjects: 14119
Study 26888572 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation with mitral regurgitation (MR) or aortic regurgitation (AR)
Number of subjects: 14119
Study 26888572 — intervention group
Group type: COMPARATOR
Intervention: No significant valve disease (no SVD)
Number of subjects: 14119
Study 26888572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban in patients with MR or AR
Number of subjects: 14119
Study 24342522 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide, 120 mg, subcutaneously every 28 days for 120 weeks
Number of subjects: 300
Study 24342522 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 300
Study 24342522 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide
Number of subjects: 300
Study 22035883 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose methotrexate (50mg/m² intramuscularly on days 0 and 4)
Number of subjects: 157
Study 22035883 — intervention group
Group type: COMPARATOR
Intervention: Single-dose methotrexate (50mg/m² intramuscularly on day 0)
Number of subjects: 157
Study 22035883 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose methotrexate
Number of subjects: 157
Study 22035883 — intervention group
Group type: COMPARATOR
Intervention: Single-dose methotrexate
Number of subjects: 157
Study 20538165 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL selective delipidated plasma infusions
Number of subjects: 28
Study 20538165 — intervention group
Group type: COMPARATOR
Intervention: Control plasma apheresis/reinfusions
Number of subjects: 28
Study 18834244 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive MOX
Number of subjects: 92
Study 18834244 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive DOX
Number of subjects: 92
Study 18834244 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 92
Study 15983685 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine treatment
Number of subjects: 48
Study 15983685 — intervention group
Group type: COMPARATOR
Intervention: No glutamine treatment (Control)
Number of subjects: 48
Study 11792919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 ml of 1% lidocaine)
Number of subjects: 90
Study 11792919 — intervention group
Group type: COMPARATOR
Intervention: Control (5 ml of 0.9% sodium chloride)
Number of subjects: 90
Study 11792919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and Control
Number of subjects: 90
Study 10619657 — intervention group
Group type: EXPERIMENTAL
Intervention: Scene processing
Number of subjects: 0
Study 10619657 — intervention group
Group type: EXPERIMENTAL
Intervention: Face processing
Number of subjects: 0
Study 8912502 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid (GLA) 2.8 gm/day
Number of subjects: 56
Study 8912502 — intervention group
Group type: COMPARATOR
Intervention: sunflower seed oil (placebo)
Number of subjects: 56
Study 1897808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (0.5 mg x 1 terbutaline)
Number of subjects: 16
Study 1897808 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol metered dose inhaler (0.1 mg x 2 albuterol)
Number of subjects: 16
Study 6224500 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 1881
Study 6224500 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1881
Study 31356986 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 146
Study 30178064 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive residential lead-exposure reduction intervention
Number of subjects: 355
Study 30178064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 355